Taipei Exchange On News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Taipei exchange on. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Taipei Exchange On Today - Breaking & Trending Today

GBC seeks US authorization for oral COVID-19 drug

Golden Biotechnology Corp (GBC, 國鼎) plans to apply for emergency use authorization in the US for its experimental COVID-19 drug after positive results in its phase 2 clinical trials, the company said.
GBC on Wednesday announced some of the results from randomized, double-blind and placebo-controlled studies in phase 2 clinical trials of its COVID-19 oral drug antroquinonol, dubbed Hocena, for the treatment of people hospitalized with mild-to-moderate COVID-19 symptoms.
In the trials, 97.9 percent of people recovered by the 14th day after being given the drug and all participants recovered by the 28th day, GBC spokesman Alan Tseng (曾木增) said yesterday.
“Recovered” meant ....

T Ai Pei , Liu Sheng Yung , Chen Yung Chi , Alan Tseng , Senhwa Biosciences Inc , Labcorp Drug Development , Taipei Exchange On , Taipei Exchange , Golden Biotechnology Corp , Taipei Times , Kao Shih Ching , Biotechnology Corp , Emerging Stock Board , The Taipei Times ,

《TAIPEI TIMES》 GBC seeks US authorization for oral COVID-19 drug - 焦點

By Kao Shih-ching / Staff reporterGolden Biotechnology Corp (GBC, 國鼎) plans to apply for emergency use authorization in the US for its experimental COVID-19 drug after positive results in its phase 2 clinical trials, the company said. ....

T Ai Pei , Liu Sheng Yung , Chen Yung Chi , Alan Tseng , Senhwa Biosciences Inc , Labcorp Drug Development , Taipei Exchange On , Taipei Exchange , Golden Biotechnology Corp , Taipei Times , Kao Shih Ching , Biotechnology Corp , Emerging Stock Board , Iberty Times Net ,

Intech testing new asthma inhaler with eye on US market

Intech Biopharm Corp (益得生技) has started testing the effects of a metered-dose inhaler generic of Teva Pharmaceutical Industries Ltd’s ProAir, and expects to gain marketing approval by 2023, it said yesterday.
The company, which developed SYN011 to treat acute asthma, received approval from the US Food and Drug Administration in August to study the biochemical and physiological effects of the drug in a phase 3 clinical trial, Intech spokesperson Hugues Hung (洪堯國) told the Taipei Times.
The company has recruited about 200 participants with asthma for the test, dividing them into control and experiment groups to receive a placebo, a brand name ....

T Ai Pei , Teva Proair , Peter Lin , Cipla Ltd , Intech Biopharm Corp , Merck Sharp Dohme Ltd , Taipei Exchange On , Taipei Times , Lupin Ltd , Teva Pharmaceutical Industries Ltd Proair , Kao Shih Ching , Biopharm Corp , Teva Pharmaceutical Industries Ltd , Drug Administration , Hugues Hung , Taipei Exchange , India Based Cipla Ltd , Merck Sharp , Dohme Ltd , The Taipei Times ,